Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.85% | -30.51% | 3.04% | 6.72% | 0.85% |
| Total Depreciation and Amortization | 7.92% | 48.00% | -3.07% | -39.29% | -0.88% |
| Total Amortization of Deferred Charges | -- | -- | -3.00% | -- | -- |
| Total Other Non-Cash Items | 7.78% | 200.56% | 3.03% | -539.52% | -0.94% |
| Change in Net Operating Assets | 8.03% | 121.08% | 3.13% | -126.69% | 1.00% |
| Cash from Operations | -7.85% | -13.45% | 3.04% | -2.79% | 0.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -2.44% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | 0.78% |
| Cash from Investing | -- | -- | -2.44% | 112.91% | 0.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 13.10% | 0.00% | -1.20% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -107.06% | 0.00% | -60.50% | 0.00% |
| Cash from Financing | -7.82% | -116.62% | -3.02% | -62.06% | -0.86% |
| Foreign Exchange rate Adjustments | 20.00% | 123.81% | 4.55% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -20.00% | -200.00% | -16.67% | 220.00% | 0.00% |
| Net Change in Cash | -7.85% | -65.91% | 3.04% | -167.39% | 0.86% |